As all the articles published in Therapeutics (ISSN: 2813-9909) are of open access format, you have free and unlimited access to the full text of all articles. We invite you to read our most viewed papers in 2024, which are listed below:
1. “Application of Invasive Bacteria for the Delivery of Anti-Cancer Therapeutics”
by Rasaq Akinsola and Kumaran Narayanan
Therapeutics 2024, 1(2), 124-141; https://doi.org/10.3390/therapeutics1020011
Available online: https://www.mdpi.com/2813-9909/1/2/11
2. “Dilemmas in Diagnosis and Management of Temporal Bone Fractures and Their Sequelae”
by Taylor Powell, Cameron Robicheaux, Rhian Germany and Gauri Mankekar
Therapeutics 2024, 1(2), 52-63; https://doi.org/10.3390/therapeutics1020007
Available online: https://www.mdpi.com/2813-9909/1/2/7
3. “Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model”
by Arman Romiani, Daniella Pettersson, Nishte Rassol, Klara Simonsson, Hana Bakr, Dan E. Lind, Anikó Kovács, Johan Spetz, Ruth H. Palmer, Bengt Hallberg et al.
Therapeutics 2024, 1(1), 4-21; https://doi.org/10.3390/therapeutics1010003
Available online: https://www.mdpi.com/2813-9909/1/1/3
4. “Management of Left Atrial Tachyrhythms in the Setting of HFpEF with Pulsed-Field Ablation: Treating Fire with Water?”
by Tyler Chinedu Chinyere and Ikeotunye Royal Chinyere
Therapeutics 2024, 1(1), 42-51; https://doi.org/10.3390/therapeutics1010006
Available online: https://www.mdpi.com/2813-9909/1/1/6
5. “Safety and Efficacy of Primary EUS-Guided Choledochoduodenostomy for Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis”
by Eugene Annor, Harishankar Gopakumar, Ishaan Vohra and Srinivas R. Puli
Therapeutics 2024, 1(1), 22-33; https://doi.org/10.3390/therapeutics1010004
Available online: https://www.mdpi.com/2813-9909/1/1/4
6. “Applying Evidence Synthesis for Constructing Directed Acyclic Graphs to Identify Causal Pathways Affecting U.S. Early-Stage Non-Small Cell Lung Cancer Treatment Receipt and Overall Survival”
by Naiya Patel, Seyed M. Karimi, Bert Little, Michael Egger and Demetra Antimisiaris
Therapeutics 2024, 1(2), 64-94; https://doi.org/10.3390/therapeutics1020008
Available online: www.mdpi.com/2813-9909/1/2/8
7. “Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma”
by Katja Seipel, Lynn Benninger, Ulrike Bacher and Thomas Pabst
Therapeutics 2024, 1(2), 95-105; https://doi.org/10.3390/therapeutics1020009
Available online: https://www.mdpi.com/2813-9909/1/2/9
8. “Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome”
by Natasha Venugopal, Hyma V. Polimera, Jessica Santucci, Erik Washburn and Elizabeth Federici
Therapeutics 2024, 1(1), 34-41; https://doi.org/10.3390/therapeutics1010005
Available online: https://www.mdpi.com/2813-9909/1/1/5
9. “Systematic Literature Review of Epaxial Paraspinal Schwannomas: Differential Diagnosis and Treatment Approaches”
by Wassim Khalil, Roula Khalil, Alexandre Meynard, Alexandre Perani, Elodie Chaudruc, Mathilde Duchesne, Karine Durand, François Caire and Henri Salle
Therapeutics 2024, 1(2), 106-123; https://doi.org/10.3390/therapeutics1020010
Available online: https://www.mdpi.com/2813-9909/1/2/10
We invite you to read and submit relevant papers to the journal Therapeutics.
Therapeutics Editorial Office
